Peter Johnston DTRG Participant
Why did you participate in diabetes technology clinical research?
It was a simple and practical way in which I could assist with diabetes research. It had increased importance to me because my granddaughter had been diagnosed at age 2 1/2 with type I diabetes in December 2019. Before this event I had considered an insulin pump and CGM as inappropriate for me. When Mabel was fitted with the system, I chose to do the same to support her. The research was focussed on reducing the frequency of infusion site changes. This is a sensitive issue for my granddaughter because she has almost no fatty tissue for the site, and was unsurprisingly sensitive to the pain of site establishment.
What impact has it had on you?
Participation in the trial demonstrated to me the extent of the pre-release testing associated with “medical device” products. It also demonstrated the professionalism and care provided by the research team – both of which were exemplary. The research also gave me an encouraging preview of new product innovations.
What impact has it had on your family? To a slightly lesser extent, my participation in the study had a similar impact on my broader family as it did for me. There was no negative aspect.
work life? The trial had zero impact on my working life. In fact, the COVID-19 protocols reduced the potential impact on my work through the home-visit research process.
life in general? There were no negative impacts on my general life during the research.
Would you recommend clinical research to others?
I would recommend research participation to others. I don’t have friends with Type I diabetes, but should that change, I would recommend it to them.
I would share all of the above in support of participation. There are minuscule inconveniences (e.g. wearing two insulin pumps and CGMs for a few days), but I consider them insignificant.
What have been your impressions being a participant in Clinical Research?
Medical and research staff went to extremes to ensure my safety, understanding of the process, and comfort during the trial. They also configured the process to minimise inconvenience when planning visits and reviews.
Would you participate again?
In a heartbeat.
Because this is essential to ensure the safety and efficacy of new innovations and products which are aimed at improving the lives of Type I diabetes patients.